Endo International — UBS Healthcare Conference 2017
23 slides from Endo International's conference presentation, May 23, 2017

Slide 1: Endo International plc UBS Healthcare Conference
Endo International plc UBS Healthcare Conference May 23, 2017 ©2017 Endo Pharmaceuticals Inc. All rights reserved. Exhibit 99.1

Slide 2: Forward Looking Statements; Non-GAAP Financial Measures
Forward Looking Statements; Non-GAAP Financial Measures This presentation contains forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Canadian securities legislation. Statements including words such as “believes,” “expects,” “anticipates,” “inte

Slide 3: Endo Overview
Endo Overview ©2017 Endo Pharmaceuticals Inc. All rights reserved. Q1 2017 Total Sales: $1,038m U.S. Generic Pharmaceuticals: U.S. Branded Pharmaceuticals: International Pharmaceuticals: $250m $722m $65m U.S. Generic Pharmaceuticals Differentiated technologies Strong pipeline of FTFs and ANDAs 4th l

Slide 4: Our Priorities for 2017 and Beyond
1 Reshape our Organization for Success Focus on differentiated/intelligent product selection Drive EBITDA margin improvements through operational execution and continuous improvements De-lever 3-4x range over time; committed to a highly disciplined capital allocation approach 3 Drive Margin Expansio

Slide 5: U.S. Generics: Overview
U.S. Generics: Overview ©2017 Endo Pharmaceuticals Inc. All rights reserved. Q1 2017 Rev. Q1 2016 Rev. YoY ∆%* U.S. Generics Base $236 $347 (32%) Sterile Injectables $151 $124 22% New Launches & Alternative Dosages $334 $112 198% Q1 2017 U.S. Generics Sales: $722m U.S. Generics Base Sterile Injectab

Slide 6: U.S. Generics: Full Suite of Technology Capabilities with a Robust Pipeline
U.S. Generics: Full Suite of Technology Capabilities with a Robust Pipeline Endo has become a more diversified company with expanded and differentiated capabilities, including polypeptides Highly compliant manufacturing with annual capacity of ~20 billion extended units Tablets (IR / ER) Bupropion E

Slide 7: U.S. Generics: 2017 Progress and Select Milestones
U.S. Generics: 2017 Progress and Select Milestones ©2017 Endo Pharmaceuticals Inc. All rights reserved. * Market value defined by IMS sales for 12 months Select Potential FTF/FTM Opportunities SABRIL® (vigabatrin for oral solution) – received FDA approval – launch in 2017 PYLERA® (bismuth subcitrate

Slide 8: U.S. Branded: Overview
U.S. Branded: Overview [1] Products included within Other Specialty include TESTOPEL®, NASCOBAL® Nasal Spray, and AVEED®. [2] Products included within Established Products include legacy pain products OPANA® ER, PERCOCET®, VOLTAREN® Gel, LIDODERM as well as other established products including, but

Slide 9: U.S. Branded: XIAFLEX in Cellulite
U.S. Branded: XIAFLEX® in Cellulite ©2017 Endo Pharmaceuticals Inc. All rights reserved. Data presented at Aesthetica Super Symposium (American Society of Plastic Surgeons) and American Academy of Dermatology (AAD) Plans to initiate Ph3 in 2H 2017 Commercial assessment ongoing – we are preparing to

Slide 10: International Pharmaceuticals: Overview
International Pharmaceuticals: Overview ©2017 Endo Pharmaceuticals Inc. All rights reserved. Q1 2017 Rev. Q1 2016 Rev. YoY ∆%* Paladin & other[1] $29 $34 (13%) Litha & Somar $36 $37 (4%) Q1 2017 International Sales: $65m Paladin & other[1] Litha & Somar [1] Includes sales from Endo Ventures Limited

Slide 11: Q1 2017: Financial Results (Adjusted Continuing Operations)
Q1 2017: Financial Results (Adjusted Continuing Operations)[1][2] ©2017 Endo Pharmaceuticals Inc. All rights reserved. (US $M) Q1 2017 Q1 2016 Y/Y change Revenue $1,038 $964 8% Gross Margin 61.1% 59.5% 160 bps Operating Income $437 $359 22% Income from Continuing Operations $275 $241[3] 14% Effectiv

Slide 12: 2017 Financial Guidance (Continuing Operations)
2017 Financial Guidance (Continuing Operations*) ©2017 Endo Pharmaceuticals Inc. All rights reserved. * Continuing Operations includes Endo and Par and excludes ASTORA (formerly known as AMS Women’s Health) Measure FY 2017 Financial Guidance Revenue $3.45B - $3.60B Adjusted EBITDA $1.50B - $1.58B Ad

Slide 13: Our Priorities for 2017 and Beyond
1 Reshape our Organization for Success Focus on differentiated/intelligent product selection Drive EBITDA margin improvements through operational execution and continuous improvements De-lever 3-4x range over time; committed to a highly disciplined capital allocation approach 3 Drive Margin Expansio

Slide 14: Endo International plc UBS Healthcare Conference
Endo International plc UBS Healthcare Conference May 23, 2017 ©2017 Endo Pharmaceuticals Inc. All rights reserved.

Slide 15: Appendix
Appendix ©2017 Endo Pharmaceuticals Inc. All rights reserved.

Slide 16: 2017: Cash Flow Update
2017: Cash Flow Update [1] FY ’17 Guidance includes restructuring and integration related costs of ~$30M of restructuring expenses related primarily to the Pain/Branded Restructuring, ~$20M of Severance costs related to the Corporate and R&D restructuring, ~$20M in restructuring costs related to the

Slide 17: Debt Refinancing Results in Enhanced Operational Flexibility
Debt Refinancing Results in Enhanced Operational Flexibility ©2017 Endo Pharmaceuticals Inc. All rights reserved. Maturity Profile prior to Refinancing ($ millions) Maturity Profile after Refinancing ($ millions) Summary In April 2017, Endo announced debt refinancing Issued a new ~$3.4 billion 7-yea

Slide 18: U.S. Generics: Competitive Advantage
U.S. Generics: Competitive Advantage BENEFITS of a Big Generic Company Breadth of Product Portfolio Strong Trade Presence Established Corporate Infrastructure With the STRENGTHS of an Agile Company Every Product is Important Focused on US Market Quick Decision Making Ability to Execute Quickly ©2017

Slide 19: Cash Conversion Cycle
Cash Conversion Cycle ©2017 Endo Pharmaceuticals Inc. All rights reserved.

Slide 20: Reconciliation of Non-GAAP Measures
Reconciliation of Non-GAAP Measures ©2017 Endo Pharmaceuticals Inc. All rights reserved.

Slide 21: Reconciliation of Non-GAAP Measures
Reconciliation of Non-GAAP Measures ©2017 Endo Pharmaceuticals Inc. All rights reserved.

Slide 22: Reconciliation of Non-GAAP Measures
Reconciliation of Non-GAAP Measures ©2017 Endo Pharmaceuticals Inc. All rights reserved.

Slide 23: Reconciliation of Non-GAAP Measures
Reconciliation of Non-GAAP Measures ©2017 Endo Pharmaceuticals Inc. All rights reserved.
Source: SEC EDGAR · 8-K filed May 23, 2017
More decks from Endo International PLC
Corporate Update (November 2023)18 slides · Nov 6, 2023
Corporate Update (February 2023)19 slides · Feb 14, 2023
Corporate Update (December 2022)6 slides · Dec 6, 2022
Investor Presentation (August 2022)72 slides · Aug 17, 2022
Q4 2021 Earnings Presentation21 slides · Feb 28, 2022
J.P. Morgan Healthcare Conference 202213 slides · Jan 11, 2022